NCT00641641View on ClinicalTrials.gov

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2011

Conditions
HIV Infection
Interventions
DRUG

Tenofovir + emtricitabine + raltegravir.

TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.

Trial Locations (4)

2010

St Vincent's Hospital, Darlinghurst, Sydney

407 Doctors, Sydney

Holdsworth House Medical Practice, Sydney

Taylor Square Private Clinic, Sydney

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Kirby Institute

OTHER_GOV

NCT00641641 - The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection | Biotech Hunter | Biotech Hunter